Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
412 Leser
Artikel bewerten:
(2)

Lyv Launches in the UK to Support The 500,000 Patients Going Private for Weight Loss Treatment

Online pharmacy enters booming weight loss market with end to end patient care model as private prescriptions surge

Lyv Launches in the UK to Support The 500,000 Patients Going Private For Weight Loss Treatment

LONDON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- A UK online pharmacy has entered the rapidly expanding weight loss treatment market with a service designed for patients who obtain GLP-1 prescriptions privately and then struggle to access adequate follow-up care. Lyv provides weight loss medications alongside integrated nutritional support and ongoing clinical monitoring.

The timing reflects surging private demand for obesity medications. Latest figures show 1.6 million UK adults have used weight loss drugs in the past twelve months, with the vast majority purchasing through private channels rather than the NHS. However, recent clinical research has identified that more than one in five users experience nutritional deficiencies during treatment, raising questions about the quality of aftercare being provided across the sector.

Lyv has been designed to tackle this problem directly by keeping clinical oversight, dispensing, logistics, and patient support within a single, connected model rather than fragmenting responsibilities across multiple contractors. This approach is intended as a deliberate alternative to transaction-focused services in the online pharmacy market, where patients often lose contact with providers once payment has been processed.

"Many people are finding it easy to start treatment but difficult to get answers when they need them weeks or months later," a spokesperson for Lyv stated. "Lyv keeps the same team involved from consultation through to delivery and beyond, so there is always someone who knows your history and can respond when issues come up."

The service targets a patient population estimated at around 500,000 people in the UK who are accessing weight loss prescriptions privately. NHS provision of GLP 1 medications remains restricted to people meeting specific clinical thresholds, leaving significant unmet demand that has been absorbed by online providers and private clinics. Concerns have been raised that some of these services prioritise volume over safety, with minimal clinical interaction beyond the initial prescription approval.

Lyv operates under a model in which warehousing, delivery, and customer care are kept within the same operational framework rather than outsourced, as is common in the online pharmacy sector. This structure supports more consistent care standards and allows the service to respond quickly to emerging patient needs without delays between third-party vendors. Patients receive regular check-ins during treatment, guidance on managing reduced appetite safely, and direct access to pharmacy staff when side effects or concerns arise.

"We own the entire process from prescription approval to what happens six months into treatment," the spokesperson said. "That accountability matters when you are dealing with medications that fundamentally change how people eat and how their body absorbs nutrients."

Lyv was developed with the stricter regulatory environment around online prescribing of weight management medicines in mind and includes two way clinical communication, GP contact where appropriate, and documentation systems designed for regulatory inspection. The company believes providers that have built operations around minimal interaction models will find compliance increasingly difficult as oversight intensifies.

Lyv is available nationwide via their website and provides access to GLP 1 weight loss treatments as well as prescriptions for erectile dysfunction and hair loss. Lyv expects demand from patients who have been unable to secure NHS access as well as those who have previously used other private services but found aftercare inadequate.

About Mediva Pharma Limited

Brown's Pharma Limited operates Lyv, a regulated online pharmacy service providing remote access to prescription treatments across the United Kingdom. The company maintains integrated operations covering clinical assessment, dispensing, logistics and patient aftercare. Brown's Pharma is registered with UK pharmacy regulators and adheres to applicable professional and legal standards.

Contact

Media Relations
Mediva Pharmacy
web@medivapharma.co.uk

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7b531bcd-6be9-44cf-a9c4-d021d74d5204


© 2026 GlobeNewswire (Europe)
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.